Med. 2026 Jun 12;7(6):101144. doi: 10.1016/j.medj.2026.101144.
ABSTRACT
Diabetic retinal disease remains a leading cause of vision loss, with current treatment limited by frequent injections and poor adherence. Ongoing clinical trials are evaluating topical therapies, sustained delivery systems, and gene therapy as alternatives to current gold standard treatments. The field is shifting toward earlier, more personalized, and more durable disease-modifying strategies.
PMID:42285040 | DOI:10.1016/j.medj.2026.101144